Skip to content

A Randomized Controlled Trial of metformin in the treatment of psoriasis

A Randomized Controlled Trial of metformin in the treatment of psoriasis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012096
Enrollment
Unknown
Registered
2017-07-23
Start date
2017-08-01
Completion date
Unknown
Last updated
2017-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Experimental group:metformin + Apply Halometasone Cream + Calcipotriol Ointment + silicone oil urea ointment
Control:Apply Halometasone Cream + Calcipotriol Ointment + silicone oil urea ointment

Sponsors

dermatology of PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age2 =18 years old; 2. plaque psoriasis, PASI score = 12 points; 3. signed informed consent; 4. subjects who are able to follow research procedures.

Exclusion criteria

Exclusion criteria: 1. moderate (grade 3a) and severe renal insufficiency (CrCl <45ml / min or EGFR <45ml / min / 1.73m2) or other subjects with certain underlying diseases using metformin may increase its risk; 2. subjects with severe medical illness (cardiovascular, respiratory, endocrine disease); 3. subjects with metformin or its components allergic or hypersensitive; 4. Patients with other skin diseases other than psoriasis; 5. patients who have received psoriasis system treatment (glucocorticoids, immunosuppressive agents, retinoic acid derivatives, biological agents) within six months; 6. acute drip type, pustular disease type, red psoriasis patients; 7. active infection in patients; 8. patients who have been or are taking metformin or who use other hypoglycemic agents (including insulin) or who are diagnosed with diabetes during the hospital; 9. Pregnant or lactating women. Including the study stage of pregnancy-bearing women of childbearing age; 10. Subjects were participating in other clinical trials, or subjects were involved in other clinical trials within 30 days prior to screening; 11. subjects who can not communicate or do not follow the instructions; 12. Researchers who are not eligible to participate in the study of the subject; 13. Subjects with prohibited combination medication will be used during the study period.

Design outcomes

Primary

MeasureTime frame
PASI Score;

Countries

China

Contacts

Public ContactChengxin Li

PLA General Hospital

chengxinderm@163.com+86 15210866656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026